Solitary solutions to an androgen-deprivation prostate cancer treatment model

被引:3
|
作者
Telksnys, T. [1 ]
Timofejeva, I. [1 ]
Navickas, Z. [1 ]
Marcinkevicius, R. [2 ]
Mickevicius, R. [3 ]
Ragulskis, M. [1 ]
机构
[1] Kaunas Univ Technol, Ctr Nonlinear Syst, Studentu 50-147, LT-51368 Kaunas, Lithuania
[2] Kaunas Univ Technol, Dept Software Engn, Studentu 50-415, LT-51368 Kaunas, Lithuania
[3] Lithuanian Univ Hlth Sci, Urol Clin, Eiveniu 2, LT-50009 Kaunas, Lithuania
关键词
androgen deprivation therapy; prostate cancer model; solitary solution; IDENTIFICATION; SYSTEMS;
D O I
10.1002/mma.6168
中图分类号
O29 [应用数学];
学科分类号
070104 ;
摘要
A model of androgen deprivation treatment for prostate cancer is considered in this paper. Bright/dark solitary solutions to the model are constructed using inverse balancing and generalized differential operator techniques. It is shown that solitary solutions correspond to biomedically relevant sets of model parameters. Dynamical properties of solitary solutions are analyzed in the phase plane. It is demonstrated that such solutions closely reflect the real-world phenomena observed during androgen deprivation treatment. Computational experiments are used to illustrate these effects.
引用
收藏
页码:3995 / 4006
页数:12
相关论文
共 50 条
  • [11] Reimbursement Policy and Androgen-Deprivation Therapy for Prostate Cancer
    Aragon-Ching, Jeanny B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (06): : 579 - 580
  • [12] Utilizing metformin to enhance the efficacy of androgen-deprivation therapy in the treatment of prostate cancer
    Klotz, L.
    Venier, N.
    Vandersluis, A.
    Besla, R.
    Fleshner, N.
    Pollak, M. N.
    Venkateswaran, V.
    Colquhoun, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [13] Androgen-deprivation therapy promotes immune suppression in a murine model of prostate cancer
    Krolewski, John J.
    Sha, Kai
    Nastiuk, Kent L.
    CANCER RESEARCH, 2019, 79 (13)
  • [14] Fisetin as an adjuvant treatment in prostate cancer patients receiving androgen-deprivation therapy
    Di Lorenzo, Giuseppe
    Scafuri, Luca
    Costabile, Ferdinando
    Pepe, Liuba
    Scognamiglio, Anna
    Crocetto, Felice
    Guerra, Germano
    Buonerba, Carlo
    FUTURE SCIENCE OA, 2022, 8 (03):
  • [15] Adverse effects of androgen-deprivation therapy in prostate cancer and their management
    Rhee, Handoo
    Gunter, Jennifer H.
    Heathcote, Peter
    Ho, Ken
    Stricker, Phillip
    Corcoran, Niall M.
    Nelson, Colleen C.
    BJU INTERNATIONAL, 2015, 115 : 3 - 13
  • [16] Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
    Smith, Matthew R.
    Egerdie, Blair
    Toriz, Narciso Hernandez
    Feldman, Robert
    Tammela, Teuvo L. J.
    Saad, Fred
    Heracek, Jiri
    Szwedowski, Maciej
    Ke, Chunlei
    Kupic, Amy
    Leder, Benjamin Z.
    Goessl, Carsten
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (08): : 745 - 755
  • [17] Metabolic and cardiovascular risks of androgen-deprivation therapy for prostate cancer
    Nambudiri, Vinod E.
    Keating, Nancy L.
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2010, 5 (04) : 531 - 537
  • [18] Androgen-Deprivation Therapy and the Risk of Stroke in Patients With Prostate Cancer
    Azoulay, Laurent
    Yin, Hui
    Benayoun, Serge
    Renoux, Christel
    Boivin, Jean-Francois
    Suissa, Samy
    EUROPEAN UROLOGY, 2011, 60 (06) : 1244 - 1250
  • [19] Reimbursement Policy and Androgen-Deprivation Therapy for Prostate Cancer.
    Shahinian, Vahakn B.
    Kuo, Yong-Fang
    Gilbert, Scott M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (19): : 1822 - 1832
  • [20] Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
    Shore, Neal D.
    Saad, Fred
    Cookson, Michael S.
    George, Daniel J.
    Saltzstein, Daniel R.
    Tutrone, Ronald
    Akaza, Hideyuki
    Bossi, Alberto
    van Veenhuyzen, David F.
    Selby, Bryan
    Fan, Xiaolin
    Kang, Vicky
    Walling, Jackie
    Tombal, Bertrand
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (23): : 2187 - 2196